Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75645 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL20703229 | 0.89 | — | — | |
| SCHEMBL14801159 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL23525863 | 0.78 | — | — | |
| SCHEMBL28345952 | 0.77 | — | — | |
| SCHEMBL860069 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL7554361 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL14697303 | 0.75 | — | — | |
| SCHEMBL20898974 | 0.74 | — | — | |
| Trifluoroacetic Acid SCHEMBL932054 | 0.73 | PKM (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 622 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122070282-A | Pyrazole-1-carboxamides as RIP1 kinase inhibitors | 比西切姆有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4737450-A1 | HETEROAROMATIC FORMAMIDE COMPOUNDS AND USES THEREOF IN MEDICINE | Longwood Pharmaceuticals (Hangzhou) Co., Ltd (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12583855-B2 | RET selective inhibitor, preparation method therefor and use thereof | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4045036-B1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-1732893-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | Pfizer Japan, Inc. (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1727793-A1 | SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXYGENASE-1 - CYCLOOXYGENASE-2 INHIBITORS, AND THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005077896-A1 | SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXYGENASE-1-CYCLOOXYGENASE-2 INHIBITORS, AND THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| US-20050182041-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | LABORATOIOS DE DR. ESTEVE S.A. (ES) | 2005-08-18 | — | — | US | disclosed |
| CN-1633414-A | Compound (I) | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | CN | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
| US-4927926-A | BACTERICIDES | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 1990-05-22 | — | — | US | disclosed |